25 XP   0   0   10

Glenmark Life Sciences Limited
Buy, Hold or Sell?

Let's analyse Glenmark Life Sciences Limited together

PenkeI guess you are interested in Glenmark Life Sciences Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Glenmark Life Sciences Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Glenmark Life Sciences Limited

I send you an email if I find something interesting about Glenmark Life Sciences Limited.

Quick analysis of Glenmark Life Sciences Limited (30 sec.)










What can you expect buying and holding a share of Glenmark Life Sciences Limited? (30 sec.)

How much money do you get?

How much money do you get?
INR1.51
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
INR174.51
Expected worth in 1 year
INR201.90
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
INR153.37
Return On Investment
18.8%

For what price can you sell your share?

Current Price per Share
INR814.95
Expected price per share
INR649.90 - INR906.00
How sure are you?
50%

1. Valuation of Glenmark Life Sciences Limited (5 min.)




Live pricePrice per Share (EOD)

INR814.95

Intrinsic Value Per Share

INR185.33 - INR214.75

Total Value Per Share

INR359.83 - INR389.26

2. Growth of Glenmark Life Sciences Limited (5 min.)




Is Glenmark Life Sciences Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$256.5m$246.5m$10m3.9%

How much money is Glenmark Life Sciences Limited making?

Current yearPrevious yearGrowGrow %
Making money$56m$50.2m$5.7m10.3%
Net Profit Margin21.6%19.7%--

How much money comes from the company's main activities?

3. Financial Health of Glenmark Life Sciences Limited (5 min.)




What can you expect buying and holding a share of Glenmark Life Sciences Limited? (5 min.)

Welcome investor! Glenmark Life Sciences Limited's management wants to use your money to grow the business. In return you get a share of Glenmark Life Sciences Limited.

What can you expect buying and holding a share of Glenmark Life Sciences Limited?

First you should know what it really means to hold a share of Glenmark Life Sciences Limited. And how you can make/lose money.

Speculation

The Price per Share of Glenmark Life Sciences Limited is INR814.95. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Glenmark Life Sciences Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Glenmark Life Sciences Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR174.51. Based on the TTM, the Book Value Change Per Share is INR6.85 per quarter. Based on the YOY, the Book Value Change Per Share is INR106.23 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR31.50 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Glenmark Life Sciences Limited.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.460.1%0.460.1%0.410.1%0.340.0%0.340.0%
Usd Book Value Change Per Share0.080.0%0.080.0%1.270.2%0.420.1%0.420.1%
Usd Dividend Per Share0.380.0%0.380.0%0.130.0%0.180.0%0.180.0%
Usd Total Gains Per Share0.460.1%0.460.1%1.400.2%0.600.1%0.600.1%
Usd Price Per Share4.71-4.71-5.51-2.04-2.04-
Price to Earnings Ratio10.31-10.31-13.43-4.75-4.75-
Price-to-Total Gains Ratio10.25-10.25-3.93-7.09-7.09-
Price to Book Ratio2.25-2.25-2.74-1.00-1.00-
Price-to-Total Gains Ratio10.25-10.25-3.93-7.09-7.09-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share9.7794
Number of shares102
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.380.18
Usd Book Value Change Per Share0.080.42
Usd Total Gains Per Share0.460.60
Gains per Quarter (102 shares)46.9360.71
Gains per Year (102 shares)187.73242.85
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
11543417872171233
230867366144342476
3463101554216513719
4617134742288684962
57711689303608541205
6925201111843210251448
71079235130650411961691
81234268149457613671934
91388302168264815382177
101542335187072017092420

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%5.00.00.0100.0%5.00.00.0100.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%5.00.00.0100.0%5.00.00.0100.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%5.00.00.0100.0%5.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%5.00.00.0100.0%5.00.00.0100.0%

Fundamentals of Glenmark Life Sciences Limited

About Glenmark Life Sciences Limited

Glenmark Life Sciences Limited engages in the development, manufacture, and supply of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. It offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for the treatment of cardiovascular disease; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for the treatment of central nervous system disease; Remogliflozin, Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for the treatment of diabetes; Etoricoxib, Lornoxicam, Zolmitriptan, and Frovatriptan for pain management; and Olaparib, Palbociclib, Enzalutamide, and Ruxolitinib for oncology treatment, as well as Atovaquone, an anti-parasitic and Adapalene, a dermatology product. The company also provides contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited operates as a subsidiary of Nirma Limited.

Fundamental data was last updated by Penke on 2024-04-09 11:14:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is fair priced.

1.1. Profitability of Glenmark Life Sciences Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Glenmark Life Sciences Limited earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Glenmark Life Sciences Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 21.6% means that ₹0.22 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Glenmark Life Sciences Limited:

  • The MRQ is 21.6%. The company is making a huge profit. +2
  • The TTM is 21.6%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ21.6%TTM21.6%0.0%
TTM21.6%YOY19.7%+1.9%
TTM21.6%5Y20.5%+1.1%
5Y20.5%10Y20.5%0.0%
1.1.2. Return on Assets

Shows how efficient Glenmark Life Sciences Limited is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Glenmark Life Sciences Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • 17.3% Return on Assets means that Glenmark Life Sciences Limited generated ₹0.17 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Glenmark Life Sciences Limited:

  • The MRQ is 17.3%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 17.3%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ17.3%TTM17.3%0.0%
TTM17.3%YOY16.9%+0.3%
TTM17.3%5Y18.2%-1.0%
5Y18.2%10Y18.2%0.0%
1.1.3. Return on Equity

Shows how efficient Glenmark Life Sciences Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Glenmark Life Sciences Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • 21.8% Return on Equity means Glenmark Life Sciences Limited generated ₹0.22 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Glenmark Life Sciences Limited:

  • The MRQ is 21.8%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 21.8%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ21.8%TTM21.8%0.0%
TTM21.8%YOY20.4%+1.5%
TTM21.8%5Y104.4%-82.6%
5Y104.4%10Y104.4%0.0%

1.2. Operating Efficiency of Glenmark Life Sciences Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Glenmark Life Sciences Limited is operating .

  • Measures how much profit Glenmark Life Sciences Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Glenmark Life Sciences Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 29.1% means the company generated ₹0.29  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Glenmark Life Sciences Limited:

  • The MRQ is 29.1%. The company is operating very efficient. +2
  • The TTM is 29.1%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ29.1%TTM29.1%0.0%
TTM29.1%YOY28.0%+1.2%
TTM29.1%5Y29.1%0.0%
5Y29.1%10Y29.1%0.0%
1.2.2. Operating Ratio

Measures how efficient Glenmark Life Sciences Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.72 means that the operating costs are ₹0.72 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Glenmark Life Sciences Limited:

  • The MRQ is 0.722. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.722. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.722TTM0.7220.000
TTM0.722YOY0.727-0.005
TTM0.7225Y0.714+0.008
5Y0.71410Y0.7140.000

1.3. Liquidity of Glenmark Life Sciences Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Glenmark Life Sciences Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 3.67 means the company has ₹3.67 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Glenmark Life Sciences Limited:

  • The MRQ is 3.668. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.668. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.668TTM3.6680.000
TTM3.668YOY4.595-0.927
TTM3.6685Y2.194+1.474
5Y2.19410Y2.1940.000
1.3.2. Quick Ratio

Measures if Glenmark Life Sciences Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Glenmark Life Sciences Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 2.54 means the company can pay off ₹2.54 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Glenmark Life Sciences Limited:

  • The MRQ is 2.545. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.545. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.545TTM2.5450.000
TTM2.545YOY3.116-0.572
TTM2.5455Y1.476+1.068
5Y1.47610Y1.4760.000

1.4. Solvency of Glenmark Life Sciences Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Glenmark Life Sciences Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Glenmark Life Sciences Limited to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.21 means that Glenmark Life Sciences Limited assets are financed with 20.9% credit (debt) and the remaining percentage (100% - 20.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Glenmark Life Sciences Limited:

  • The MRQ is 0.209. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.209. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.209TTM0.2090.000
TTM0.209YOY0.169+0.040
TTM0.2095Y0.542-0.333
5Y0.54210Y0.5420.000
1.4.2. Debt to Equity Ratio

Measures if Glenmark Life Sciences Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Glenmark Life Sciences Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 26.4% means that company has ₹0.26 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Glenmark Life Sciences Limited:

  • The MRQ is 0.264. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.264. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.264TTM0.2640.000
TTM0.264YOY0.203+0.061
TTM0.2645Y4.232-3.968
5Y4.23210Y4.2320.000

2. Market Valuation of Glenmark Life Sciences Limited

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Glenmark Life Sciences Limited generates.

  • Above 15 is considered overpriced but always compare Glenmark Life Sciences Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 10.31 means the investor is paying ₹10.31 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Glenmark Life Sciences Limited:

  • The EOD is 21.384. Based on the earnings, the company is fair priced.
  • The MRQ is 10.309. Based on the earnings, the company is underpriced. +1
  • The TTM is 10.309. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD21.384MRQ10.309+11.074
MRQ10.309TTM10.3090.000
TTM10.309YOY13.425-3.116
TTM10.3095Y4.747+5.562
5Y4.74710Y4.7470.000
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Glenmark Life Sciences Limited:

  • The EOD is 69.726. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 33.616. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 33.616. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD69.726MRQ33.616+36.110
MRQ33.616TTM33.6160.000
TTM33.616YOY12.079+21.537
TTM33.6165Y9.139+24.477
5Y9.13910Y9.1390.000
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Glenmark Life Sciences Limited is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 2.25 means the investor is paying ₹2.25 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Glenmark Life Sciences Limited:

  • The EOD is 4.670. Based on the equity, the company is fair priced.
  • The MRQ is 2.251. Based on the equity, the company is underpriced. +1
  • The TTM is 2.251. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD4.670MRQ2.251+2.419
MRQ2.251TTM2.2510.000
TTM2.251YOY2.736-0.485
TTM2.2515Y0.998+1.254
5Y0.99810Y0.9980.000
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Glenmark Life Sciences Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--6.8476.8470%106.227-94%34.902-80%34.902-80%
Book Value Per Share--174.509174.5090%167.662+4%88.716+97%88.716+97%
Current Ratio--3.6683.6680%4.595-20%2.194+67%2.194+67%
Debt To Asset Ratio--0.2090.2090%0.169+24%0.542-61%0.542-61%
Debt To Equity Ratio--0.2640.2640%0.203+30%4.232-94%4.232-94%
Dividend Per Share--31.49731.4970%10.500+200%14.699+114%14.699+114%
Eps--38.11138.1110%34.174+12%28.499+34%28.499+34%
Free Cash Flow Per Share--11.68811.6880%37.985-69%17.524-33%17.524-33%
Free Cash Flow To Equity Per Share---19.945-19.9450%31.554-163%4.202-575%4.202-575%
Gross Profit Margin--0.9470.9470%0.924+3%0.921+3%0.921+3%
Intrinsic Value_10Y_max--214.754--------
Intrinsic Value_10Y_min--185.325--------
Intrinsic Value_1Y_max--24.514--------
Intrinsic Value_1Y_min--23.820--------
Intrinsic Value_3Y_max--71.372--------
Intrinsic Value_3Y_min--67.447--------
Intrinsic Value_5Y_max--115.480--------
Intrinsic Value_5Y_min--106.222--------
Market Cap99853378650.000+52%48140925878.80048140925878.8000%56215387600.000-14%20871262695.760+131%20871262695.760+131%
Net Profit Margin--0.2160.2160%0.197+10%0.205+5%0.205+5%
Operating Margin--0.2910.2910%0.280+4%0.2910%0.2910%
Operating Ratio--0.7220.7220%0.727-1%0.714+1%0.714+1%
Pb Ratio4.670+52%2.2512.2510%2.736-18%0.998+126%0.998+126%
Pe Ratio21.384+52%10.30910.3090%13.425-23%4.747+117%4.747+117%
Price Per Share814.950+52%392.900392.9000%458.800-14%170.340+131%170.340+131%
Price To Free Cash Flow Ratio69.726+52%33.61633.6160%12.079+178%9.139+268%9.139+268%
Price To Total Gains Ratio21.254+52%10.24710.2470%3.931+161%7.089+45%7.089+45%
Quick Ratio--2.5452.5450%3.116-18%1.476+72%1.476+72%
Return On Assets--0.1730.1730%0.169+2%0.182-5%0.182-5%
Return On Equity--0.2180.2180%0.204+7%1.044-79%1.044-79%
Total Gains Per Share--38.34338.3430%116.727-67%49.601-23%49.601-23%
Usd Book Value--256584840.000256584840.0000%246517440.000+4%130441992.000+97%130441992.000+97%
Usd Book Value Change Per Share--0.0820.0820%1.275-94%0.419-80%0.419-80%
Usd Book Value Per Share--2.0942.0940%2.012+4%1.065+97%1.065+97%
Usd Dividend Per Share--0.3780.3780%0.126+200%0.176+114%0.176+114%
Usd Eps--0.4570.4570%0.410+12%0.342+34%0.342+34%
Usd Free Cash Flow--17184960.00017184960.0000%55849560.000-69%25766616.000-33%25766616.000-33%
Usd Free Cash Flow Per Share--0.1400.1400%0.456-69%0.210-33%0.210-33%
Usd Free Cash Flow To Equity Per Share---0.239-0.2390%0.379-163%0.050-575%0.050-575%
Usd Market Cap1198240543.800+52%577691110.546577691110.5460%674584651.200-14%250455152.349+131%250455152.349+131%
Usd Price Per Share9.779+52%4.7154.7150%5.506-14%2.044+131%2.044+131%
Usd Profit--56035320.00056035320.0000%50246880.000+12%44723088.000+25%44723088.000+25%
Usd Revenue--259346400.000259346400.0000%254785680.000+2%218686512.000+19%218686512.000+19%
Usd Total Gains Per Share--0.4600.4600%1.401-67%0.595-23%0.595-23%
 EOD+4 -4MRQTTM+0 -0YOY+19 -175Y+19 -1710Y+19 -17

3.2. Fundamental Score

Let's check the fundamental score of Glenmark Life Sciences Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1521.384
Price to Book Ratio (EOD)Between0-14.670
Net Profit Margin (MRQ)Greater than00.216
Operating Margin (MRQ)Greater than00.291
Quick Ratio (MRQ)Greater than12.545
Current Ratio (MRQ)Greater than13.668
Debt to Asset Ratio (MRQ)Less than10.209
Debt to Equity Ratio (MRQ)Less than10.264
Return on Equity (MRQ)Greater than0.150.218
Return on Assets (MRQ)Greater than0.050.173
Total8/10 (80.0%)

3.3. Technical Score

Let's check the technical score of Glenmark Life Sciences Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.172
Ma 20Greater thanMa 50802.695
Ma 50Greater thanMa 100806.743
Ma 100Greater thanMa 200768.274
OpenGreater thanClose759.950
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-03-312020-03-312021-03-312022-03-312023-03-31
Total Other Income Expense Net -54,360-173,190-227,550-680,240-907,790767,780-140,010418,530278,520



Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets27,021,470
Total Liabilities5,639,400
Total Stockholder Equity21,382,070
 As reported
Total Liabilities 5,639,400
Total Stockholder Equity+ 21,382,070
Total Assets = 27,021,470

Assets

Total Assets27,021,470
Total Current Assets18,503,390
Long-term Assets8,518,080
Total Current Assets
Cash And Cash Equivalents 2,838,230
Short-term Investments 964,780
Net Receivables 8,067,660
Inventory 6,041,710
Other Current Assets 591,010
Total Current Assets  (as reported)18,503,390
Total Current Assets  (calculated)18,503,390
+/-0
Long-term Assets
Property Plant Equipment 8,242,440
Intangible Assets 180,010
Other Assets 94,860
Long-term Assets  (as reported)8,518,080
Long-term Assets  (calculated)8,517,310
+/- 770

Liabilities & Shareholders' Equity

Total Current Liabilities5,044,140
Long-term Liabilities595,260
Total Stockholder Equity21,382,070
Total Current Liabilities
Short-term Debt 22,650
Accounts payable 3,965,610
Other Current Liabilities 296,760
Total Current Liabilities  (as reported)5,044,140
Total Current Liabilities  (calculated)4,285,020
+/- 759,120
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt170,920
Other Liabilities 424,340
Long-term Liabilities  (as reported)595,260
Long-term Liabilities  (calculated)595,260
+/-0
Total Stockholder Equity
Common Stock245,050
Retained Earnings 11,020,630
Accumulated Other Comprehensive Income 66,830
Other Stockholders Equity 10,049,560
Total Stockholder Equity (as reported)21,382,070
Total Stockholder Equity (calculated)21,382,070
+/-0
Other
Capital Stock245,050
Cash and Short Term Investments 3,803,010
Common Stock Shares Outstanding 122,527
Current Deferred Revenue759,120
Liabilities and Stockholders Equity 27,021,470
Net Debt -2,644,660
Net Invested Capital 21,382,070
Net Tangible Assets 21,202,060
Net Working Capital 13,459,250
Property Plant and Equipment Gross 8,242,440
Short Long Term Debt Total 193,570



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2023-03-312022-03-312021-03-312020-03-312019-03-312018-03-31
> Total Assets 
0
14,753,950
17,256,040
19,970,750
24,710,070
27,021,470
27,021,47024,710,07019,970,75017,256,04014,753,9500
   > Total Current Assets 
840
9,306,960
11,601,140
13,990,410
17,645,840
18,503,390
18,503,39017,645,84013,990,41011,601,1409,306,960840
       Cash And Cash Equivalents 
0
20,610
99,980
1,155,960
5,121,570
2,838,230
2,838,2305,121,5701,155,96099,98020,6100
       Short-term Investments 
0
57,870
207,700
241,640
51,460
964,780
964,78051,460241,640207,70057,8700
       Net Receivables 
310
5,039,620
7,281,030
7,510,040
6,742,530
8,067,660
8,067,6606,742,5307,510,0407,281,0305,039,620310
       Inventory 
380
4,008,430
4,127,750
5,134,210
5,162,440
6,041,710
6,041,7105,162,4405,134,2104,127,7504,008,430380
       Other Current Assets 
80
5,220,050
7,165,710
7,458,600
567,840
591,010
591,010567,8407,458,6007,165,7105,220,05080
   > Long-term Assets 
0
5,446,990
5,654,900
5,980,340
7,064,230
8,518,080
8,518,0807,064,2305,980,3405,654,9005,446,9900
       Property Plant Equipment 
10
5,303,000
5,498,080
5,789,860
6,763,360
8,242,440
8,242,4406,763,3605,789,8605,498,0805,303,00010
       Intangible Assets 
0
63,510
71,680
79,110
103,800
180,010
180,010103,80079,11071,68063,5100
       Other Assets 
0
79,230
84,370
110,600
196,300
94,860
94,860196,300110,60084,37079,2300
> Total Liabilities 
0
13,872,700
13,239,120
12,443,280
4,166,950
5,639,400
5,639,4004,166,95012,443,28013,239,12013,872,7000
   > Total Current Liabilities 
14,830
13,804,140
13,074,640
12,214,400
3,839,960
5,044,140
5,044,1403,839,96012,214,40013,074,64013,804,14014,830
       Short-term Debt 
0
210
210
-72,900
16,800
22,650
22,65016,800-72,9002102100
       Short Long Term Debt 
0
210
210
0
0
0
0002102100
       Accounts payable 
130
1,873,930
2,034,670
2,225,950
3,244,040
3,965,610
3,965,6103,244,0402,225,9502,034,6701,873,930130
       Other Current Liabilities 
100
11,906,460
11,063,930
9,988,450
34,010
296,760
296,76034,0109,988,45011,063,93011,906,460100
   > Long-term Liabilities 
0
68,560
164,480
228,880
326,990
595,260
595,260326,990228,880164,48068,5600
       Other Liabilities 
0
68,560
164,480
228,880
314,950
424,340
424,340314,950228,880164,48068,5600
> Total Stockholder Equity
0
881,250
4,016,920
7,527,470
20,543,120
21,382,070
21,382,07020,543,1207,527,4704,016,920881,2500
   Retained Earnings 
0
0
3,997,320
7,507,870
10,213,530
11,020,630
11,020,63010,213,5307,507,8703,997,32000
   Accumulated Other Comprehensive Income 
0
0
0
0
34,980
66,830
66,83034,9800000
   Capital Surplus 000000
   Treasury Stock000000



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue21,612,200
Cost of Revenue-10,140,880
Gross Profit11,471,32011,471,320
 
Operating Income (+$)
Gross Profit11,471,320
Operating Expense-5,469,330
Operating Income6,007,5706,001,990
 
Operating Expense (+$)
Research Development651,770
Selling General Administrative91,500
Selling And Marketing Expenses246,180
Operating Expense5,469,330989,450
 
Net Interest Income (+$)
Interest Income157,660
Interest Expense-5,470
Other Finance Cost-157,660
Net Interest Income-5,470
 
Pretax Income (+$)
Operating Income6,007,570
Net Interest Income-5,470
Other Non-Operating Income Expenses0
Income Before Tax (EBT)6,286,0905,729,050
EBIT - interestExpense = 6,286,090
6,286,090
4,675,080
Interest Expense5,470
Earnings Before Interest and Taxes (EBIT)6,291,5606,291,560
Earnings Before Interest and Taxes (EBITDA)6,712,500
 
After tax Income (+$)
Income Before Tax6,286,090
Tax Provision-1,616,480
Net Income From Continuing Ops4,669,6104,669,610
Net Income4,669,610
Net Income Applicable To Common Shares4,669,610
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses15,610,210
Total Other Income/Expenses Net278,5205,470
 

Technical Analysis of Glenmark Life Sciences Limited
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Glenmark Life Sciences Limited. The general trend of Glenmark Life Sciences Limited is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Glenmark Life Sciences Limited's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Glenmark Life Sciences Limited.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 767.05 < 906.00.

The bearish price targets are: 676.50 > 652.50 > 649.90.

Tweet this
Glenmark Life Sciences Limited Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Glenmark Life Sciences Limited. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Glenmark Life Sciences Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Glenmark Life Sciences Limited. The current macd is 4.61179403.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Glenmark Life Sciences Limited price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Glenmark Life Sciences Limited. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Glenmark Life Sciences Limited price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Glenmark Life Sciences Limited Daily Moving Average Convergence/Divergence (MACD) ChartGlenmark Life Sciences Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Glenmark Life Sciences Limited. The current adx is 19.29.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Glenmark Life Sciences Limited shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Glenmark Life Sciences Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Glenmark Life Sciences Limited. The current sar is 863.56.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Glenmark Life Sciences Limited Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Glenmark Life Sciences Limited. The current rsi is 53.17. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Glenmark Life Sciences Limited Daily Relative Strength Index (RSI) ChartGlenmark Life Sciences Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Glenmark Life Sciences Limited. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Glenmark Life Sciences Limited price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Glenmark Life Sciences Limited Daily Stochastic Oscillator ChartGlenmark Life Sciences Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Glenmark Life Sciences Limited. The current cci is -13.18999654.

Glenmark Life Sciences Limited Daily Commodity Channel Index (CCI) ChartGlenmark Life Sciences Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Glenmark Life Sciences Limited. The current cmo is 7.27191797.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Glenmark Life Sciences Limited Daily Chande Momentum Oscillator (CMO) ChartGlenmark Life Sciences Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Glenmark Life Sciences Limited. The current willr is -41.79287761.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Glenmark Life Sciences Limited is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Glenmark Life Sciences Limited Daily Williams %R ChartGlenmark Life Sciences Limited Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Glenmark Life Sciences Limited.

Glenmark Life Sciences Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Glenmark Life Sciences Limited. The current atr is 37.58.

Glenmark Life Sciences Limited Daily Average True Range (ATR) ChartGlenmark Life Sciences Limited Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Glenmark Life Sciences Limited. The current obv is 14,693,074.

Glenmark Life Sciences Limited Daily On-Balance Volume (OBV) ChartGlenmark Life Sciences Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Glenmark Life Sciences Limited. The current mfi is 55.20.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Glenmark Life Sciences Limited Daily Money Flow Index (MFI) ChartGlenmark Life Sciences Limited Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Glenmark Life Sciences Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-10ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-07RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-18ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-04BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-19MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Glenmark Life Sciences Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Glenmark Life Sciences Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.172
Ma 20Greater thanMa 50802.695
Ma 50Greater thanMa 100806.743
Ma 100Greater thanMa 200768.274
OpenGreater thanClose759.950
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Glenmark Life Sciences Limited with someone you think should read this too:
  • Are you bullish or bearish on Glenmark Life Sciences Limited? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Glenmark Life Sciences Limited? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Glenmark Life Sciences Limited

I send you an email if I find something interesting about Glenmark Life Sciences Limited.


Comments

How you think about this?

Leave a comment

Stay informed about Glenmark Life Sciences Limited.

Receive notifications about Glenmark Life Sciences Limited in your mailbox!